drugset / Trial / NCT00097825

Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men

NCT00097825

Phase 3 Completed 288 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this study is to determine the effectiveness and safety of an annual intravenous treatment of zoledronic acid for the treatment of osteoporosis in men. All patients will receive calcium and vitamin D supplements.

Timeline

Start
2004-04
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified Intravenous

Indications